Intellectual Property

Cambium Medical Technologies has twelve (12) patents pending, which will translate into patent coverage through the early 2030’s assuming the prosecution of no new patents which will not be the case.

Cambium engaged Georgia Tech graduate bioengineering students in 2015 to develop a proprietary Elate Ocular™ single-use package/vial, resulting in the filing of two additional patents on this innovation in April/May 2015.

  Serial Number Title Filing Date Owner
US 61/501,411 Compositions, Uses, and Preparation of Platelet Lysates 6/27/2011 Emory
US 61/547,897 Compositions, Uses, and Preparation of Platelet Lysates 10/17/2011 Emory
PCT/US2012/044211 Compositions, Uses, and Preparation of Platelet Lysates 6/26/2012 Emory
US 14/128,448 Compositions, Uses, and Preparation of Platelet Lysates 6/26/2012 Emory
CN 2012800367931 Compositions, Uses, and Preparation of Platelet Lysates 6/26/2012 Emory
EP 12804449.2 Compositions, Uses, and Preparation of Platelet Lysates 6/26/2012 Emory
CA2,840,568 Compositions, Uses, and Preparation of Platelet Lysates 6/26/2012 Emory
UA 2012275562 Compositions, Uses, and Preparation of Platelet Lysates 6/26/2012 Emory
JP 2014-518918 Compositions, Uses, and Preparation of Platelet Lysates 6/26/2012 Emory
HK 14109251.9 Compositions, Uses, and Preparation of Platelet Lysates 10/30/2014 Emory
  US Provisional Appl Dual Chamber Dispensing Device 4/23/2015 Cambium
  US Design Appl Dual Chamber Dispensing Device 5/29/2015 Cambium

Indicates exclusive worldwide licence to Cambium, all fields of use - 5/14/14


Cambium filed in October 2014 trademark applications for Elate Ocular and Aurarix with the US PTO.  Both marks have been approved for publication.